Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ioannis Parodis

Showing results (51-60 of 189) with videos related to

Pageof 19
Sort By:
Frontiers in Medicine|October 7, 2024
Editorial: Autoantibodies for diagnostics, prognostics, and surveillance in autoimmune diseaseHelena Enocsson, Ingrid E Lundberg, Martin Herrmann, et al.
Mediterranean Journal of Rheumatology|August 28, 2024
Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus ErythematosusDionysis Nikolopoulos, Maria Helena Lourenço, Roberto Depascale, et al.
RMD Open|March 7, 2025
Holistic approaches in systemic lupus erythematosus: do physicians avoid addressing difficult-to-treat but highly relevant symptoms?Ioannis Parodis, Chris Wincup, Zahi Touma, et al.
Rheumatology (Oxford, England)|April 5, 2024
Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activityDionysis Nikolopoulos, Nursen Cetrez, Julius Lindblom, et al.
Rheumatology (Oxford, England)|June 4, 2019
Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosusIoannis Parodis, Petter Johansson, Alvaro Gomez, et al.
Rheumatology and Therapy|May 31, 2024
Cardiovascular Risk Evaluation in Psoriatic Arthritis by Aortic Stiffness and the Systemic Coronary Risk Evaluation (SCORE): Results of the Prospective PSOCARD Cohort StudyKonstantinos Triantafyllias, Stefanie Liverakos, Muthuraman Muthuraman, et al.
Lupus Science & Medicine|December 10, 2016
Interferon (IFN)-λ is a potential mediator in lupus nephritisAgneta Zickert, Vilija Oke, Ioannis Parodis, et al.
Frontiers in Immunology|December 15, 2023
Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosusJulius Lindblom, Lorenzo Beretta, Maria Orietta Borghi, et al.
Frontiers in Medicine|May 16, 2022
Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus ErythematosusIoannis Parodis, Alvaro Gomez, Julius Lindblom, et al.
Frontiers in Immunology|April 21, 2022
Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A <i>Post-Hoc</i> Analysis of Three Phase III Clinical Trials of BelimumabIoannis Parodis, Alvaro Gomez, Jun Weng Chow, et al.
Pageof 19

Showing results (51-60 of 189) with videos related to

Sort By:
Pageof 19
Frontiers in Medicine|October 7, 2024
Editorial: Autoantibodies for diagnostics, prognostics, and surveillance in autoimmune diseaseHelena Enocsson, Ingrid E Lundberg, Martin Herrmann, et al.
Mediterranean Journal of Rheumatology|August 28, 2024
Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus ErythematosusDionysis Nikolopoulos, Maria Helena Lourenço, Roberto Depascale, et al.
RMD Open|March 7, 2025
Holistic approaches in systemic lupus erythematosus: do physicians avoid addressing difficult-to-treat but highly relevant symptoms?Ioannis Parodis, Chris Wincup, Zahi Touma, et al.
Rheumatology (Oxford, England)|April 5, 2024
Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activityDionysis Nikolopoulos, Nursen Cetrez, Julius Lindblom, et al.
Rheumatology (Oxford, England)|June 4, 2019
Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosusIoannis Parodis, Petter Johansson, Alvaro Gomez, et al.
Rheumatology and Therapy|May 31, 2024
Cardiovascular Risk Evaluation in Psoriatic Arthritis by Aortic Stiffness and the Systemic Coronary Risk Evaluation (SCORE): Results of the Prospective PSOCARD Cohort StudyKonstantinos Triantafyllias, Stefanie Liverakos, Muthuraman Muthuraman, et al.
Lupus Science & Medicine|December 10, 2016
Interferon (IFN)-λ is a potential mediator in lupus nephritisAgneta Zickert, Vilija Oke, Ioannis Parodis, et al.
Frontiers in Immunology|December 15, 2023
Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosusJulius Lindblom, Lorenzo Beretta, Maria Orietta Borghi, et al.
Frontiers in Medicine|May 16, 2022
Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus ErythematosusIoannis Parodis, Alvaro Gomez, Julius Lindblom, et al.
Frontiers in Immunology|April 21, 2022
Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A <i>Post-Hoc</i> Analysis of Three Phase III Clinical Trials of BelimumabIoannis Parodis, Alvaro Gomez, Jun Weng Chow, et al.
Pageof 19